Liglinra (Linagliptin)

Linagliptin works by selectively blocking the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion, reduces glucagon release, and slows gastric emptying, collectively lowering blood glucose levels after meals and throughout the day.

The appropriate dose of Liglinra is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Limited clinical data are available for linagliptin use in pregnancy and lactation. Because safety has not been established, the drug is generally not recommended for pregnant or nursing women unless the potential benefit justifies the potential risk, as assessed by a qualified clinician.

To request Liglinra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Liglinra (linagliptin) shares the same class mechanism as sitagliptin, saxagliptin, and alogliptin but differs in pharmacokinetics. Linagliptin has a high affinity for DPP‑4 and is primarily excreted unchanged via the bile, allowing use without dose adjustment in mild to moderate renal impairment, unlike some alternatives that require renal dosing adjustments.

Liglinra should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Liglinra is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and maintain consistent timing each day.

The most serious adverse events linked to linagliptin include acute pancreatitis, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and rare autoimmune skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Liglinra is contraindicated in individuals with a known hypersensitivity to linagliptin or any component of the formulation. It should also be avoided in patients with severe hepatic impairment and used with caution in those with a history of pancreatitis or significant renal dysfunction, as determined by a healthcare professional.